Neurogene Inc.(NGNE)

Biotechnology · New York City, NY

$25.45-1.02 (-3.85%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

EBITDA Yield: N/A

Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.

The EBITDA yield is N/A as of 2026-10-06T21:27:42.523Z.

Stored calculation inputs

Calculation as of: 2026-10-06T21:27:42.523Z.

Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.

TTM operating EBITDA · period ending 2026-06-30: -116,551,000
Quote market capitalization: 402,169,197
Total debt · period ending 2026-06-30: 8,345,000
Cash · period ending 2026-06-30: 112,485,000

FMP input reference: 8656b7a9da6ad27e4e3bee00a1f051c5b9ad9ad1f17b43070ca9e23e03b297bf

EV/EBITDA|Earnings Yield|OCF Yield|FCF Yield|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

NGNE EBITDA Yield Metrics

EBITDA YIELD

N/A

NGNE Competitors' EBITDA Yield

NGNE

Neurogene Inc.

Current

Market Cap

$402.17M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

MYGN

Myriad Genetics, Inc.

vs NGNE

Market Cap

$404.24M

EBITDA Yield

N/A

TTM Avg

3.45%

3Y Avg

4.91%

5Y Avg

6.50%

AVIR

Atea Pharmaceuticals, Inc.

vs NGNE

Market Cap

$405.74M

EBITDA Yield

N/A

TTM Avg

951.70%

3Y Avg

394.96%

5Y Avg

394.96%

CARL

Carlsmed, Inc.

vs NGNE

Market Cap

$397.99M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

EIKN

Eikon Therapeutics, Inc. Common Stock

vs NGNE

Market Cap

$406.58M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Shoulder Innovations, Inc.

vs NGNE

Market Cap

$396.93M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

SRTA

Strata Critical Medical, Inc.

vs NGNE

Market Cap

$411.00M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

MPLT

MapLight Therapeutics, Inc.

vs NGNE

Market Cap

$411.21M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

RZLT

Rezolute, Inc.

vs NGNE

Market Cap

$415.98M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

SENS

Senseonics Holdings, Inc.

vs NGNE

Market Cap

$416.27M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EBITDA YIELD	TTM	3Y	5Y
Neurogene Inc. (NGNE)	$402.17M	N/A	N/A	N/A	N/A
Myriad Genetics, Inc. (MYGN)vs ›	$404.24M	N/A	3.45%	4.91%	6.50%
Atea Pharmaceuticals, Inc. (AVIR)vs ›	$405.74M	N/A	951.70%	394.96%	394.96%
Carlsmed, Inc. (CARL)vs ›	$397.99M	N/A	N/A	N/A	N/A
Eikon Therapeutics, Inc. Common Stock (EIKN)vs ›	$406.58M	N/A	N/A	N/A	N/A
Shoulder Innovations, Inc. (SI)vs ›	$396.93M	N/A	N/A	N/A	N/A
Strata Critical Medical, Inc. (SRTA)vs ›	$411.00M	N/A	N/A	N/A	N/A
MapLight Therapeutics, Inc. (MPLT)vs ›	$411.21M	N/A	N/A	N/A	N/A
Rezolute, Inc. (RZLT)vs ›	$415.98M	N/A	N/A	N/A	N/A
Senseonics Holdings, Inc. (SENS)vs ›	$416.27M	N/A	N/A	N/A	N/A

EBITDA Yield Formula & Definition

EBITDA Yield = TTM EBITDA / Enterprise Value

EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EBITDA Yield: N/A

NGNE EBITDA Yield Metrics

NGNE Competitors' EBITDA Yield

EBITDA Yield Formula & Definition

Related Metrics